Six decades on from the double helix, genomics remains a read-only technology. Our ability to intervene at the genome level in adult humans is essentially zero. Sequence data is used to guide research, to diagnose and to inform - but therapeutic and prophylactic intervention is still limited to the downstream, diverse and biologically messy consequences of genomic variations.
As long as genomics focuses on diagnostics and analysis, it will realize only a fraction of a percent of its potential. Mote is developing somatic editing technology to intervene directly, safely and precisely in the genomes of adult humans to tackle cancer, retroviral diseases and genetic disorders where they start - in the DNA.